Skip to main content

Advertisement

SpringerLink
Log in

TYPE 2 DIABETES MELLITUS IN 2020

SGLT2 inhibitors in people with and without T2DM

  • Year in Review
  • Published:

From Nature Reviews Endocrinology

View current issue Sign up to alerts

Heart failure and chronic kidney disease are frequent causes of morbidity and mortality in people with type 2 diabetes mellitus. Cardiovascular outcome trials have confirmed benefits of sodium–glucose co-transporter 2 inhibitors on cardiovascular events, cardiovascular deaths, hospitalization for heart failure and renal outcomes. These benefits now extend to people with and without type 2 diabetes mellitus.

Key advances

  • Sodium–glucose co-transporter 2 inhibitors significantly reduce the risk of major cardiovascular events, cardiovascular death or hospitalization for heart failure and progression of chronic kidney disease in people with type 2 diabetes mellitus (T2DM) with or without atherosclerotic cardiovascular disease2.

  • Dapagliflozin and empagliflozin have shown significant beneficial effects on the composite outcome of worsening of heart failure or cardiovascular death in patients with New York Heart Association Class 2, 3 or 4 heart failure with or without T2DM3,5.

  • Dapagliflozin and empagliflozin significantly reduce hospitalization for heart failure, and dapagliflozin significantly reduces cardiovascular death irrespective of T2DM status3,5.

  • Dapagliflozin and empagliflozin have significant beneficial effects on renal outcomes in people with and without T2DM5,6.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Potential mechanisms of SGLT2is in cardiorenal protection.

References

  1. Birkeland, K. I. et al. Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study. Diabetes Obes. Metab. 22, 1607–1618 (2020).

    Article  CAS  Google Scholar 

  2. Qiu, M. et al. SGLT2 inhibitors for prevention of cardiorenal events in people with type 2 diabetes without cardiorenal disease: A meta-analysis of large randomized trials and cohort studies. Pharmacol. Res. 161, 105175 (2020).

    Article  CAS  Google Scholar 

  3. McMurray, J. J. V. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381, 1995–2008 (2019).

    Article  CAS  Google Scholar 

  4. Cannon, C. P. et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N. Engl. J. Med. 383, 1425–1435 (2020).

    Article  CAS  Google Scholar 

  5. Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 383, 1413–1424 (2020).

    Article  CAS  Google Scholar 

  6. Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436–1446 (2020).

    Article  CAS  Google Scholar 

  7. Zannad, F. et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 396, 819–829 (2020).

    Article  Google Scholar 

Download references

Acknowledgements

K.K. is supported by the National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands (ARC EM) and the NIHR Leicester Biomedical Research Centre (BRC).

Author information

Authors and Affiliations

  1. Diabetes Research Centre, University of Leicester, Leicester, UK

    Kamlesh Khunti

Authors
  1. Kamlesh Khunti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kamlesh Khunti.

Ethics declarations

Competing interests

K.K. has acted as a consultant, speaker or received grants for investigator-initiated studies for AstraZeneca, Bayer, Berlin-Chemie AG/Menarini Group, Boehringer Ingelheim, Janssen, Lilly, Merck Sharp & Dohme, Napp, Novartis, Novo Nordisk and Sanofi-Aventis.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Khunti, K. SGLT2 inhibitors in people with and without T2DM. Nat Rev Endocrinol 17, 75–76 (2021). https://doi.org/10.1038/s41574-020-00453-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41574-020-00453-2

  • Springer Nature Limited

This article is cited by

Search

Navigation